Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.67 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | GCGR | P47871 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.47 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL944522 | 0.85 | IGF2BP2 (0.56) | KCNMA1TRPV1NPC1RAB9AKMT2A | |
| SCHEMBL2605541 | 0.85 | KCNMA1 (0.71) | KCNMA1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL14363216 | 0.85 | MEN1 (0.70) | NPC1RAB9AKMT2AMEN1LMNA | |
| SCHEMBL6029542 | 0.84 | KCNMA1 (0.84) | KCNMA1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL2605548 | 0.83 | KCNMA1 (0.82) | KCNMA1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL2605537 | 0.81 | KCNMA1 (0.70) | KCNMA1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL5368265 | 0.80 | MEN1 (0.62) | KCNMA1TRPV1NPC1RAB9AKMT2A | |
| SCHEMBL9968283 | 0.80 | KCNMA1 (0.64) | KCNMA1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL12937567 | 0.80 | KCNMA1 (0.68) | KCNMA1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL14363236 | 0.80 | KCNMA1 (0.77) | KCNMA1NPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | KCNMA1 1503/4885TRPV1 3489/4885NPC1 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.